ID
34939
Descrição
Study ID: 101888 Clinical Study ID: FFR101888 Study Title: A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Rhinitis, Allergic, Perennial The study consists of a screening, 4 treatment periods (TP) and a follow-up visit. For each TP there is a Day-1 (D-1) and a Day1 (D1). This document contains the Serology - screen for HIV antibody, hepatitis B and C form. It has to be filled in for screening.
Palavras-chave
Versões (1)
- 2/4/19 2/4/19 -
Titular dos direitos
GlaxoSmithKline
Transferido a
February 4, 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Effect of inhaled Fluticasone furoate and cellobiose octa-acetate on electrocardiographic parameters in healthy subjects, Study-ID: 101888
Serology - screen for HIV antibody, hepatitis B and C
- StudyEvent: ODM
Similar models
Serology - screen for HIV antibody, hepatitis B and C
- StudyEvent: ODM
C0019682 (UMLS CUI-2)
C0019163 (UMLS CUI-3)
C0019196 (UMLS CUI-4)
C0036743 (UMLS CUI [1,2])
Sem comentários